Jina Yun, PharmD

Advancements in treatment include immune checkpoint inhibitors and BRAF/MEK inhibitors, though resistance remains a challenge, with lifileucel recently approved for previously treated metastatic cases.

Axitinib, cabozantinib, and lenvatinib are first-line treatment options.